Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia

• Published in: Journal of Clinical and Experimental Hematopathology Vol. 63; no. 1; pp. 43 - 48
• Main Authors: Suyama, Takahiro, Hagihara, Masao, Matsui, Naruaki, Irie, Rie, Osamura, Yoshiyuki, Sakai, Tetsuo, Watanabe, Shouichi, Umemoto, Shintarou, Miyao, Naoki
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Lymphoreticular Tissue Research 01.01.2023; JSLRT
• Subjects: Aged, 80 and over; anti-tumor immunity; Case Report; CD57 positive T cell; dasatinib; Dasatinib - adverse effects; Herpesvirus 8, Human; HHV8-negative effusion-based lymphoma; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Lymphoma; Male; pleural effusion; Pleural Effusion - chemically induced; Pleural Effusion - drug therapy; Protein Kinase Inhibitors - adverse effects; dasatinib; anti-tumor immunity; pleural effusion; CD57 positive T cell; HHV8-negative effusion-based lymphoma

We present the case of an 85-year-old male patient diagnosed with human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) that developed from long-lasting pleural effusion (PE) induced by dasatinib treatment for chronic myeloid leukemia (CML). After the onset of this disorder, dasatinib tr...